Should NSAIDs including ASA be discontinued preoperatively for laparoscopy?

Should NSAIDs including ASA be discontinued preoperatively for laparoscopy?

• A. They must be discontinued before laparoscopy
• B. They do not need to be discontinued
• C. Only aspirin should be stopped; NSAIDs may continue
• D. They should be replaced with acetaminophen

Answer: (B)

In laparoscopy the bleeding risk is relatively low, so NSAIDs including aspirin do not need to be routinely stopped before the procedure. The reasons are twofold: first, keeping antiplatelet effects in place, especially with low-dose aspirin, protects against thrombotic events if stopping could pose cardiovascular risk; second, the small, controlled bleeding typical of laparoscopic surgery is not usually worsened enough by continuing these medications to justify stopping them. Aspirin’s antiplatelet effect lasts for the life of platelets, so stopping briefly may not fully mitigate bleeding risk, and for many patients the thrombotic threat of stopping aspirin outweighs the potential for increased blood loss. Nonaspirin NSAIDs have reversible effects on platelets and do not routinely mandate discontinuation in this context. The decision is individualized if there are specific bleeding concerns or other anticoagulants involved.

In laparoscopy the bleeding risk is relatively low, so NSAIDs including aspirin do not need to be routinely stopped before the procedure. The reasons are twofold: first, keeping antiplatelet effects in place, especially with low-dose aspirin, protects against thrombotic events if stopping could pose cardiovascular risk; second, the small, controlled bleeding typical of laparoscopic surgery is not usually worsened enough by continuing these medications to justify stopping them. Aspirin’s antiplatelet effect lasts for the life of platelets, so stopping briefly may not fully mitigate bleeding risk, and for many patients the thrombotic threat of stopping aspirin outweighs the potential for increased blood loss. Nonaspirin NSAIDs have reversible effects on platelets and do not routinely mandate discontinuation in this context. The decision is individualized if there are specific bleeding concerns or other anticoagulants involved.